Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.

about

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.

Item

http://www.wikidata.org/entity/Q41125977

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Engineered factor Xa variants ...... f direct factor Xa inhibitors.

@en

type

Item

label

Engineered factor Xa variants ...... f direct factor Xa inhibitors.

@en

prefLabel

Engineered factor Xa variants ...... f direct factor Xa inhibitors.

@en

P1476

Engineered factor Xa variants ...... of direct factor Xa inhibitors

@en

P2093

C Ruben Vosmeer

http://www.w3.org/2001/XMLSchema#string

Ka Lei Cheung

http://www.w3.org/2001/XMLSchema#string

Koen M Visscher

http://www.w3.org/2001/XMLSchema#string

Pieter H Reitsma

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of a serpin-protease complex shows inhibition by deformation

Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding

Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulat

Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex

Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis

The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa

Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa

Calibrated automated thrombin generation measurement in clotting plasma

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

P2888

s41467-017-00647-9

P304

528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41467-017-00647-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daan P Geerke

Daniël Verhoef

M H Bos

P577

2017-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28904343

http://www.w3.org/2001/XMLSchema#string

P932

5597622

http://www.w3.org/2001/XMLSchema#string